Overview

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Status:
NOT_YET_RECRUITING
Trial end date:
2031-04-03
Target enrollment:
Participant gender:
Summary
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
Phase:
PHASE1
Details
Lead Sponsor:
Bristol-Myers Squibb